Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Avacta (United Kingdom) | Researchclopedia

Back to institutions

Avacta (United Kingdom)

Leedscompany

57

Works

1,816

Citations

18

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research Allergic Rhinitis and Sensitization Food Allergy and Anaphylaxis Research

Top Researchers

David Jones German Cancer Research Center

1,477 works104,157 citationsh-index: 144

Recent Research

Xylosyltransferase engineering to manipulate proteoglycans in mammalian cells

Zhen Li,Himanshi Chawla,et al.

20260 citations

Advanced biosensing and bioanalysis techniques

Advanced Biosensing Techniques and Applications

Glycosylation and Glycoproteins Research

Contact Dermatitis and Allergies

Spectroscopy Techniques in Biomedical and Chemical Research

Peptidase Inhibition and Analysis

Asthma and respiratory diseases

RNA and protein synthesis mechanisms

RNA Interference and Gene Delivery

Robert C. Ford University of Central Florida

356 works42,400 citationsh-index: 62

386 works12,690 citationsh-index: 55

Robert A. Edwards University of California, Irvine

209 works11,561 citationsh-index: 48

D. A. Smith Virginia Tech

285 works9,462 citationsh-index: 52

Richard Tuli Allegheny Health Network

264 works8,732 citationsh-index: 41

964P A phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

William D. Tap,Udai Banerji,et al.

20250 citations

Abstract CT151: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates

Gëzim Lahu,Udai Banerji,et al.

20250 citations

Abstract 3139: The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

Curtis Rink,Tom Clough,et al.

20250 citations

Generating and validating renewable affimer protein binding reagents targeting SH2 domains

Sophie J. Heseltine,Gregory J. Billenness,et al.

20244 citations

646P A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

C.J. Twelves,Udai Banerji,et al.

20242 citations